Clinical Trials Logo

Filter by:
NCT ID: NCT05567354 Completed - Clinical trials for Recreational Drug Use

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users

Start date: June 10, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine the abuse potential and pharmacokinetics of PF614 compared with a non-abuse deterrent, commercially available, immediate release (IR) oxycodone hydrochloride (HCl) formulation and placebo.

NCT ID: NCT05567250 Completed - Child Development Clinical Trials

Testing a Scalable Model For ACEs-Related Care Navigation

Start date: October 5, 2022
Phase: N/A
Study type: Interventional

The study is a randomized controlled trial of a telephone-based care coordination system for families who experienced Adverse Childhood Events (ACEs). The investigators will conduct the study in partnership with Kaiser Permanente School of Medicine (KPSOM) and 2-1-1 Los Angeles County (211LA), part of a national network of 2-1-1 call centers covering 93% of the US population. The study will test the effectiveness of 211LA in increasing referrals and services for families who screen positive for ACEs.

NCT ID: NCT05567159 Completed - Healthy Clinical Trials

A Study of Donanemab (LY3002813) in Healthy Participants

Start date: October 4, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess how fast donanemab (LY3002813) gets into the blood stream and how long it takes the body to remove it when administered as single dose in healthy participants. The study will also evaluate the safety and tolerability of donanemab. The study will last up to approximately 22 weeks.

NCT ID: NCT05567029 Completed - Healthy Volunteers Clinical Trials

Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.

Start date: September 28, 2022
Phase: Phase 1
Study type: Interventional

This study will assess how safe risankizumab is and how risankizumab moves through the body of adult healthy participants. Adverse Events will be assessed. Risankizumab is an investigational drug being developed for the treatment of Crohn's Disease. Participants are randomly assigned to one of the 2 treatment groups. Approximately 198 adult healthy volunteers will be enrolled in at least 4 sites across the world. All participants will receive risankizumab as subcutaneous injections in one of the 2 different formulations. There may be higher burden for participants in this trial. Participants will be confined for 10 days and followed up for 140 days. Adverse Events and blood tests will be collected.

NCT ID: NCT05566808 Completed - Rhinoplasty Clinical Trials

Use of Allograft Cartilage in Cosmetic and Reconstructive Rhinoplasty

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

This is a single-center, blinded, controlled trial, conducted in healthy adult subjects undergoing a reconstructive or cosmetic rhinoplasty involving the use of cartilaginous graft (either non-irradiated cartilage sheet allograft compared to autologous harvest and grafting of costal cartilage).

NCT ID: NCT05566730 Completed - Cannabis Use Clinical Trials

Culturally Tailored Cannabis Use Disorder App

Start date: June 14, 2023
Phase: N/A
Study type: Interventional

The present study aims to address disparities in cannabis use outcomes among African American/Black (hereby referred to as Black) adults with cannabis use disorder (CUD). The specific aims of this study are: (1) to develop a culturally adapted, mobile app for Black cannabis users (CT-MICART) using knowledge from the current research team, published literature, expert opinion, and feedback from the Community Research Advisory Board (CRAB), (2) to pilot test CT-MICART and (3) focus on analysis of data collected as part of Aim 2.

NCT ID: NCT05566704 Completed - Clinical trials for Degenerative Disc Disease

Retrospective Modulus ALIF Study

Start date: August 18, 2022
Phase:
Study type: Observational

The primary objective of this study is to evaluate the safety and performance of the Modulus ALIF System in patients undergoing anterior lumbar interbody fusion (ALIF) as measured by reported complications, radiographic outcomes, and patient-reported outcomes.

NCT ID: NCT05566691 Completed - Anxiety Clinical Trials

Strategies for Coping With Negative Thoughts

Start date: August 29, 2022
Phase: N/A
Study type: Interventional

The primary objective of this study is to assess the impact of two strategies for coping with negative automatic thoughts (positive thinking and cognitive restructuring) on one's belief in negative thoughts and one's affect. Another main objective is to assess whether participating in a positive mood induction (versus no mood induction) prior to using one of the two coping strategies impacts belief in negative thoughts and affect. We will also explore the interaction between strategy condition and mood induction condition. As secondary outcomes, we will evaluate whether there are changes in positive thinking skills and cognitive restructuring skills and depressive symptoms after one week of using the strategy.

NCT ID: NCT05566639 Completed - Seasonal Influenza Clinical Trials

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Start date: September 14, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.

NCT ID: NCT05566379 Completed - Long COVID Clinical Trials

Mindfulness in Post Acute Sequelae of SARS-CoV-2 Infection (PASC) Dysautonomia

Start date: February 28, 2023
Phase: N/A
Study type: Interventional

The current pilot study will recruit participants experiencing new, returning, or ongoing symptoms related to COVID-19 illness for at least four weeks after being first infected with SARS-CoV-2. All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center (MARC) at University of California Los Angeles (UCLA). This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. The research team will collect self-reported measures of mental health symptoms, physical health symptoms, and demographic information before and after participants attend MAPs. Objective health measures will also be collected by the research team including an active stand test, a 6-minute walk, and a blood sample.